Conversion Chemotherapy for Technically Unresectable Colorectal Liver Metastases

Medicine (United States)

Volumn 95, Issue 20, 2016, Pages

  Basso, Michele ^a   Dadduzio, Vincenzo ^a   Ardito, Francesco ^b   Lombardi, Pasquale ^a   Strippoli, Antonia ^a   Vellone, Maria ^b   Orlandi, Armando ^a   Rossi, Sabrina ^a   Cerchiaro, Eleonora ^a   Cassano, Alessandra ^a   Giuliante, Felice ^b   Barone, Carlo ^a  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; KRAS PROTEIN, HUMAN; PLATINUM COMPLEX; PROTEIN P21;

ADULT; AGED; ARTICLE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CLINICAL ASSESSMENT; COLORECTAL LIVER METASTASIS; CONTINUOUS INFUSION; DISEASE FREE SURVIVAL; EXON; FEMALE; FOLLOW UP; HUMAN; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE; WILD TYPE; ANALOGS AND DERIVATIVES; COLORECTAL TUMOR; COMPARATIVE STUDY; GENETICS; LIVER NEOPLASMS; MIDDLE AGED; PATHOLOGY; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; SECONDARY; SURVIVAL RATE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; CAMPTOTHECIN; CETUXIMAB; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HEPATECTOMY; HUMANS; LEUCOVORIN; LIVER NEOPLASMS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PROTO-ONCOGENE PROTEINS P21(RAS); RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 85013811722     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000003722     Document Type: Article

References (22)

1. Stangl R, Altendorf-Hofmann A, Charnley RM, et al. Factory influencing the natural history of colorectal liver metastases. Lancet. 1994;343:1405-1410.
2. Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: Analysis of 1001 consecutive cases. Ann Surg. 1999;230:309-318.
3. Nordlinger B, Guiguet M, Vaillant JC, et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer. 1996;77:1254-1262.
4. Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: A model to predict long term survival. Ann Surg. 2004;240:644-657.
5. Bismuth H, Adam R, Levi F, et al. Resection of non-resectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg. 1996;224:509-522.
6. Masi G, Cupini S, Marcucci L, et al. Treatment with 5-fluorouracil/folinic acid, oxaliplatin and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer. Ann Surg Oncol. 2006;13:58-65.
7. Folprecht G, Gruenberger T, Bechstein WO, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: The CELIM randomized phase II trial. Lancet Oncol. 2010;11:38-47.
8. Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Eng J Med. 2009;360:1408-1417.
9. Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin and oxaliplatin with or without cetuximab in the first line treatment of metastatic colorectal cancer. J Clin Oncol. 2009;27:663-671.
10. Masi G, Loupakis F, Pollina L, et al. Long-Term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil, leucovorin, oxaliplatin and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. Ann Surg. 2009;249: 420-425.
11. Garufi C, Torsello A, Tumolo S, et al. Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial. Br J Cancer. 2010;103:1542-1547.
12. Ye LC, Liu TS, Wei Y, et al. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-Type unresectable colorectal liver-limited metastases. J Clin Oncol. 2013;31:1931-1938.
13. Primrose J, Falk S, Finch-Jones M, et al. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: The New EPOC randomised controlled trial. Lancet Oncol. 2014;15:601-611.
14. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-247.
15. Barone C, Nuzzo G, Cassano A, et al. Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases. Br J Cancer. 2007;97:1035-1039.
16. Fornaro L, Lonardi S, Masi G, et al. FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-Type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: A phase II trial by the Gruppo Oncologico Nord Ovest (GONO). Ann Oncol. 2013;24:2062-2067.
17. Stintzing S, von Weikersthal LF, Kiani A, et al. Independent radiological evaluation of objective response, early tumor shrinkage, and depth of response in FIRE-3 (AIO KRK-0306) in the final RAS evaluable population. ESMO. 2014. Proffered paper session (ref LBA11).
18. Mansmann UR, Sartorius U, Laubender RP, et al. Deepness of response: A quantitative analysis of its impact on post-progression survival time after first-line treatment in patients with mCRC. J Clin Oncol. 2013;31(Suppl 4)abstr 427.
19. Venook A, Niedzwiecki D, Mahoney M, et al. CALGB/SWOG 80405: Analysis of patients undergoing surgery as part of treatment strategy. ESMO. 2014. Proffered paper session (ref LBA10).
20. Heinemann V, von Weikersthal LF, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): A randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15:1065-1075.
21. Schwartzberg LS, Rivera F, Karthaus M, et al. PEAK: A randomized, multicenter phase II study of panitumumab plus modifi ed fl uorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-Type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol. 2014;32:2240-2247.
22. Folprecht G, Gruenberger T, Bechstein WO, et al. Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study). Ann Oncol. 2014;25:1018-1025.